ArticleFrontiers in oncology2026
Hyperthermic intraperitoneal chemotherapy with raltitrexed for peritoneal recurrence presenting with massive ascites following radical surgery for advanced gastric cancer: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peritoneal recurrence is the most common form of recurrence after radical gastrectomy for gastric cancer (GC) and is the main cause of death. The median survival period is 3-6 months, and the 5-year survival rate is almost zero. So far, the treatment methods recommended by various clinical guidelines for peritoneal metastasis (PM) of GC are all palliative systemic chemotherapy (SC). However, the therapeutic effect is not ideal. One possible reason is the existence of the blood-peritoneal barrier, which makes it difficult for drugs to reach the peritoneal metastatic foci fully. Based on this, surgeons have gradually attempted the intraperitoneal administration mode in clinical practice. Hyperthermic intraperitoneal chemotherapy (HIPEC) improves the anti-tumor efficacy through the synergistic effect of heat and chemotherapy drugs and has achieved good therapeutic effects in the treatment of PM of GC. Raltitrexed is mainly used for intravenous administration and intraperitoneal chemotherapy for advanced colorectal cancer. HIPEC with raltitrexed for the treatment of PM after radical gastrectomy for GC is extremely rare. This article introduces a case of advanced GC with peritoneal recurrence and a large amount of ascites 11 months after radical gastrectomy. After 5 cycles of HIPEC with raltitrexed, a favorable therapeutic effect was achieved. The patient experienced significant clinical improvement, characterized by the resolution of ascites, alleviation of symptoms, and prolonged survival, thereby creating an opportunity for subsequent comprehensive treatment. It is hoped that this case can provide a treatment option for patients with peritoneal recurrence after radical gastrectomy for GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.